Evidence map›Paper›PMID 22892130›Full record

ArticleBiochemical and biophysical research communications2012

Novel regulation of protein kinase C-η.

Deepanwita Pal, Shalini Persaud Outram, Alakananda Basu

Open access · greenAbstract read
In one paragraph

Article in Biochemical and biophysical research communications, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. METTL3-mediatedTheranostics · 2022
    Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Deepanwita PalDepartment of Molecular Biology & Immunology, University of North Texas Health Science Center, Fort Worth, TX 76107, USA.
Shalini Persaud Outram
Alakananda Basu
University of North Texas Health Science Center · US

Funding

TUMOR NECROSIS FACTOR ALPHA SIGNALING IN BREAST CANCERR01CA071727 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BASU, ALAKANANDA · 1997 to 2009
$1.3M
NCI NIH HHS CA071727NCI NIH HHS R01 CA071727
6 · The paper itself

Abstract

Protein kinase C (PKC) is the receptor for tumor promoting phorbol esters, which are potent activators of conventional and novel PKCs, but persistent treatment with phorbol esters leads to downregulation of these PKCs. However, PKCη, a novel PKC isozyme, resists downregulation by tumor-promoting phorbol esters, but little is known about how PKCη level is regulated. Phosphorylation and dephosphorylation play an important role in regulating activity and stability of PKCs. In the present study, we have investigated the molecular mechanism of PKCη regulation. Several PKC activators, including phorbol 12,13-dibutyrate, 12-O-tetradecanoylphorbol-13-acetate and indolactam V caused upregulation of PKCη, whereas the general PKC inhibitor Gö 6983, but not the conventional PKC inhibitor Gö 6976 led to the downregulation of PKCη. Upregulation of PKCη was associated with an increase in phosphorylation of PKCη. Silencing of phosphoinositide-dependent kinase-1, which phosphorylates PKCη at the activation loop, failed to prevent PKC activator-induced upregulation of PKCη. Knockdown of PKCε but not PKCα inhibited PKC activator-induced upregulation of PKCη. Thus, our results suggest that the regulation of PKCη is unique and PKCε is required for the PKC activator-induced upregulation of PKCη.

Indexed as

CarbazolesCell Line, TumorEnzyme ActivationGene Knockdown TechniquesHEK293 CellsHumansIndolesMaleimidesPhorbol 12,13-DibutyrateProtein Kinase CProtein Kinase C-alphaProtein Kinase C-epsilonProtein Kinase InhibitorsUp-Regulation2-(1-(3-dimethylaminopropyl)-5-methoxyindol-3-yl)-3-(1H-indol-3-yl)maleimideCarbazolesGo 6976IndolesMaleimidesPhorbol 12,13-DibutyrateProtein Kinase CProtein Kinase C-alphaProtein Kinase C-epsilonprotein kinase C etaProtein Kinase Inhibitors

Identifiers

PMID22892130
PMCPMC3438288
OpenAlexW2077729695

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.